Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge

References

• Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019 Sep 18;32(4):e00031–19.
   PubMed Web of Science ®Google Scholar
• Wang M-G, Liu Z-Y, Liao X-P, et al. Retrospective data insight into the global distribution of carbapenemase-producing Pseudomonas aeruginosa. Antibiotics (Basel). 2021 May 9;10(5):548.
   PubMed Web of Science ®Google Scholar
• Al-Orphaly M, Hadi HA, Eltayeb FK, et al. Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa region. mSphere. 2021 May 19;6(3):e00202–21.
   PubMed Web of Science ®Google Scholar
• Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol. 2020 Jan;41(1):1–18.
   PubMed Web of Science ®Google Scholar
• Woodworth KR, Walters MS, Weiner LM, et al. Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms – United States, 2006–2017. MMWR Morb Mortal Wkly Rep. 2018 Apr 6;67(13):396–401.
   PubMed Web of Science ®Google Scholar
• Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP. In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals. J Thorac Dis. 2019 May;11(5):1896–1902.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002 Mar 1;34(5):634–640.
   PubMed Web of Science ®Google Scholar
• Zowawi HM, Balkhy HH, Walsh TR, et al. β-Lactamase production in key gram-negative pathogen isolates from the Arabian peninsula. Clin Microbiol Rev. 2013 Jul;26(3):361–380.
   PubMed Web of Science ®Google Scholar
• Escandón-Vargas K, Reyes S, Gutiérrez S, et al. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2017 Mar;15(3):277–297.
   PubMed Web of Science ®Google Scholar
• Yoon E-J, Jeong SH. Mobile carbapenemase genes in Pseudomonas aeruginosa. Front Microbiol. 2021 Feb 18;12:614058.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. 2019 AR Threats Report [Internet]. [cited 2019 May 8]. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html.
   Google Scholar
• Poirel L, Nordmann P, Lagrutta E, et al. Emergence of KPC-producing Pseudomonas aeruginosa in the United States. Antimicrob Agents Chemother. 2010 Jul;54(7):3072.
   PubMed Web of Science ®Google Scholar
• Walters MS, Grass JE, Bulens SN, et al. Carbapenem-resistant Pseudomonas aeruginosa at US Emerging infections program sites, 2015. Emerging Infect Dis. 2019 Jul;25(7):1281–1288.
   PubMed Web of Science ®Google Scholar
• Simner PJ, Opene BNA, Chambers KK, et al. Carbapenemase detection among carbapenem-resistant glucose-nonfermenting gram-negative bacilli. J Clin Microbiol. 2017 Sep;55(9):2858–2864.
   PubMed Web of Science ®Google Scholar
• Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP, ERACE-PA Global Study Group. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2533–2541.
   PubMed Web of Science ®Google Scholar
• Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-Tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017 Oct;61(10):e00875–17.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Hindler JA, Wong-Beringer A, et al. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2017 Dec;61(12):e01858–17.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020 Jul 11;71(2):304–310.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative Bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01968–17.
   PubMed Web of Science ®Google Scholar
• Vasoo S, Cunningham SA, Cole NC, et al. In vitro activities of Ceftazidime-Avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother. 2015 Dec;59(12):7842–7846.
   PubMed Web of Science ®Google Scholar
• Brown AC, Malik S, Huang J, et al. 484. Metallo-β-Lactamase-Positive carbapenem-resistant enterobacteriaceae and Pseudomonas aeruginosa in the antibiotic resistance laboratory network, 2017–2018. Open Forum Infect Dis. 2019 Oct 23;6(Supplement_2):S237–S237.
   Google Scholar
• Li H, Estabrook M, Jacoby GA, et al. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015 Mar;59(3):1789–1793.
   PubMed Web of Science ®Google Scholar
• Simner PJ, Johnson JK, Brasso WB, et al. Multicenter evaluation of the modified Carbapenem inactivation method and the carba NP for detection of Carbapenemase-producing Pseudomonas aeruginosa and acinetobacter baumannii. J Clin Microbiol. 2018;56(1):e01369–17.
   PubMed Web of Science ®Google Scholar
• Gill CM, Lasko MJ, Asempa TE, et al. Evaluation of the EDTA-modified Carbapenem inactivation method (eCIM) for detecting metallo-β-lactamase-producing Pseudomonas aeruginosa. J Clin Microbiol. 2020 Apr 1;e02015–19.
   PubMed Web of Science ®Google Scholar
• Traczewski MM, Carretto E, Canton R, Moore NM, Carba-R Study Team. Multicenter Evaluation of the Xpert Carba-R Assay for Detection of Carbapenemase Genes in Gram-Negative Isolates. J Clin Microbiol. 2018 Jul 26;58(8):e00272–18.
   Google Scholar
• Kanahashi T, Matsumura Y, Yamamoto M, et al. Comparison of the Xpert Carba-R and NG-test CARBA5 for the detection of carbapenemases in an IMP-type carbapenemase endemic region in Japan. J Infect Chemother. 2021 Mar;27(3):503–506.
   PubMed Web of Science ®Google Scholar
• Gill CM, Asempa TE, Tickler IA, et al. Evaluation of the Xpert Carba-R NxG assay for detection of carbapenemase genes in a global challenge set of Pseudomonas aeruginosa isolates. J Clin Microbiol. 2020 Nov 18;58(12):e01098–20.
   PubMed Web of Science ®Google Scholar
• Gill CM, Asempa TE, Nicolau DP. Development and application of a pragmatic algorithm to guide definitive carbapenemase testing to identify carbapenemase-producing Pseudomonas aeruginosa. Antibiotics (Basel). 2020 Oct 27;9(11):738.
   PubMed Web of Science ®Google Scholar
• Lasko MJ, Gill CM, Asempa TE, et al. EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP metallo-β-lactamase-producing Pseudomonas aeruginosa: an assessment of increasing EDTA concentrations. BMC Microbiol. 2020 Jul 20;20(1):220.
   PubMed Web of Science ®Google Scholar
• Tenover FC, Dela Cruz CM, Dewell S, et al. Does the presence of multiple β-lactamases in gram-negative bacilli impact the results of antimicrobial susceptibility tests and extended-spectrum β-lactamase and carbapenemase confirmation methods? J Glob Antimicrob Resist. 2020 Sep 2;23:87–93.
   PubMed Web of Science ®Google Scholar